Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIDJ2 registry cohort safety study of Cuvitru in primary immunodeficiency
jRCT2031240293Recruiting
- Sponsor
- Takeda
- Start
- Feb 2025
- Countries
- 1
01
Overview
Open-label, single-arm trial of polyvalent human immunoglobulin in Immunogenetic disorder, sponsored by Takeda. Primary endpoints: Number of participants who experience anaphylactic reaction as an adverse event, Number of participants who experience thromboembolism as an adverse event and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on jRCT2031240293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240293.